Merck & Co., Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-58.8% vs price
Base Case (Median)
-36.2% vs price
Bull Case (75th pct.)
-8.7% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-689.13 | -657.5% | High (40%) |
| PE Comparable | $78.90 | -36.2% | Medium (25%) |
| Growth Trajectory DCF | $60.90 | -50.7% | Medium (20%) |
| Graham Number | $40.98 | -66.8% | Medium (40%) |
| EV/EBITDA | $112.96 | -8.6% | Medium (20%) |
| EV/FCF | $112.83 | -8.7% | Medium (20%) |
| Earnings Power Value | $122.19 | -1.1% | Medium (50%) |
Based on 7 out of 8 methods, MRK appears overvalued at the current price of $123.60. The base case fair value of $78.90 implies 36.2% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.